Glucophage (Metformin Hydrochloride)

Glucophage is indicated for the management of type 2 diabetes mellitus, typically as part of a broader therapeutic regimen that includes diet and exercise.

• Improves glycemic control in adults with type 2 diabetes.
• May be used as initial monotherapy when lifestyle changes are insufficient.
• Can be combined with other oral antidiabetic agents or insulin to achieve target blood glucose levels.
• May be considered in patients with overweight or obesity to aid weight management as an adjunct to lifestyle measures.
• Used off‑label in some regions for polycystic ovary syndrome under medical supervision.

The safety profile of Glucophage includes a range of adverse effects that vary in frequency and severity.

Common

• Gastrointestinal upset such as nausea, abdominal discomfort, and diarrhea, which often improve with dose titration.
• A metallic taste in the mouth that may be transient.
• Decreased appetite or mild weight loss, particularly during the initial weeks of therapy.

Serious

• Lactic acidosis, a rare but potentially life‑threatening condition characterized by rapid breathing, muscle pain, and abdominal discomfort.
• Severe hypoglycemia when Glucophage is combined with insulin or sulfonylureas, requiring careful monitoring of blood glucose.
• Hepatotoxicity presenting as elevated liver enzymes or jaundice, especially in patients with pre‑existing liver disease.
• Vitamin B12 deficiency with prolonged use, which may lead to anemia or peripheral neuropathy.

When prescribing Glucophage, clinicians consider several precautionary measures to minimize risk and ensure safe use.

• Assess renal function before initiation and periodically thereafter, as reduced clearance increases the risk of accumulation.
• Avoid use in patients with known hypersensitivity to metformin or other biguanides.
• Use with caution in individuals with hepatic impairment, heart failure, or conditions predisposing to hypoxia.
• Discontinue the drug prior to any radiographic studies involving iodinated contrast agents.
• Monitor for signs of lactic acidosis, especially in the elderly or those with comorbidities.
• Evaluate vitamin B12 levels during long‑term therapy and supplement if deficiency is detected.

Glucophage may interact with other medicines, affecting its efficacy or increasing the risk of adverse events.

Avoid

• Iodinated contrast agents used for imaging studies; they can precipitate acute renal failure when combined with metformin.
• Certain cimetidine formulations that significantly reduce metformin clearance.
• Renal tubular secretion inhibitors such as probenecid, which may increase metformin plasma concentrations.

Use with caution

• Insulin and sulfonylureas, which may increase the risk of hypoglycemia.
• Diuretics that can affect renal function and alter metformin levels.
• Corticosteroids, which may raise blood glucose and require dose adjustments.
• Alcohol excess, which can potentiate lactic acidosis.
• Beta‑blockers, which can mask hypoglycemia symptoms and affect glucose control.
• Thyroid hormones, which may alter glucose metabolism and require monitoring.